Formoterol used as needed in patients with intermittent or mild persistent asthma

Respiratory Medicine

Volumn 99, Issue 4, 2005, Pages 461-470

  Chuchalin, Alexandr ^a   Kasl, Milan ^b   Bengtsson, Thomas ^c   Nihlen, Ulf ^c   Rosenborg, Johan ^d  

^a Research Institute of Pulmonology   (Russian Federation)

^b District Hospital Tábor   (Czech Republic)

^c ASTRAZENECA R AND D   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

As needed; Asthma; Formoterol

Indexed keywords

CORTICOSTEROID; FORMOTEROL; GLUCOSE; METHACHOLINE; POTASSIUM; PREDNISOLONE; PREDNISONE; SHORT ACTING DRUG; STEROID; TERBUTALINE;

ADOLESCENT; ADULT; AGED; AIRWAY CONDUCTANCE; ANALYSIS OF VARIANCE; ARTICLE; ASTHMA; BRONCHITIS; CHILD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PEAK EXPIRATORY FLOW; PHARYNGITIS; POTASSIUM BLOOD LEVEL; POWDER INHALER; PRIORITY JOURNAL; PROVOCATION TEST; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; TREMOR; VIRUS INFECTION;

EID: 14844302390     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2004.09.012     Document Type: Article

References (24)

1. Anonymous. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2002 revision, National Institutes of Health, 2002. p. 1-192
2. M. Palmqvist G. Persson L. Lazer J. Rosenborg P. Larsson J. Lötvall Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency Eur Respir J 10 1997 2484-2489
3. A. Tattersfield C. Löfdahl D. Postma et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: A randomised trial Lancet 357 2001 257-261
4. M. Sears D. Taylor C. Print et al. Regular inhaled beta-agonist treatment in bronchial asthma Lancet 336 1990 1391-1396
5. D. Taylor M. Sears G. Herbison et al. Regular inhaled beta-agonist in asthma: Effect on exacerbation and lung function Thorax 48 1993 134-138
6. P. Quanjer G. Tammeling J. Cotes O. Pedersen R. Peslin Lung volumes and forced ventilatory flows Eur Respir J 6 1993 5-40
7. P. Quanjer G. Borsboom B. Brunekreef et al. Spirometric reference values for white European children and adolescents Polgar Revisited. Pediatr Pulmonol 19 1995 135-142
8. E. Juniper D. Cockcroft F. Hargreave Histamine and methacholine inhalation tests: Tidal breathing method-laboratory procedure and standardisation 1991 AB Draco Lund, Sweden
9. N. Van den Berg M. Ossip C. Hederos H. Anttila B. Riberio P. Davies Salmeterol/fluticasone propionate (50/100 mg) in combination in a Diskus™ inhaler (Seretide™) is effective and safe in children with asthma Pediatr Pulmonol 30 2000 97-105
10. E. Bateman V. Silins M. Bogolubov Clinical equivalence of salmeterol/ fluticasone propionate in combination (50/100 mg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma Respir Med 95 2001 136-146
11. Anonymous. Serevent product information. GlaxoSmithKline, 2003, http://www.fda.gov/cder/foi/label/2003/20236slr20028_serevent_lbl.pdf.
12. M. Mann B. Chowdhury E. Sullivan R. Nicklas R. Anthracite R. Meyer Serious asthma exacerbations in asthmatics treated with high-dose formoterol Chest 124 2003 70-74
13. R. Pauwels M. Sears M. Campbell et al. Formoterol as relief medication in asthma: A worldwide safety and effectiveness trial Eur Resp Med 22 2003 787-794
14. A. Grove B. Lipworth Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients Lancet 346 1995 201-206
15. S. Jones J. Cowan E. Flannery R. Hancox G. Herbison D. Taylor Reversing acute bronchoconstriction in asthma: The effect of bronchdilator tolerance after treatment with formoterol Eur Respir J 17 2001 368-373
16. D.W. Cockcroft C.P. McParland S.A. Britto V.A. Swystun B.C. Rutherford Regular inhaled salbutamol and airway responsiveness to allergen Lancet 342 1993 833-836
17. R. Hancox R. Aldridge J. Cowan et al. Tolerance to beta-agonists during acute bronchoconstriction Eur Respir J 14 1999 283-287
18. K. Tötterman L. Huhti E. Sutinen et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients Eur Respir J 12 1998 573-579
19. J. Rosenborg T. Bengtsson P. Larsson A. Blomgren G. Persson J. Lötvall Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics Eur J Clin Pharmacol 56 2000 363-370
20. P. Barnes Beta-adrenergic receptors and their regulation Am J Respir Crit Care Med 152 1995 839-860
21. E. Seberova A. Andersson Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI Respir Med 94 2000 607-611
22. J. Rosenborg P. Larsson Z. Rott C. Böcskei M. Poczi G. Juhász Relative therapeutic index between inhaled formoterol and salbutamol in asthmatic patients Respir Med 96 2002 412-417
23. J. Malolepszy G. Böszöményi Nagy O. Selroos P. Larsson R. Brander Safety of formoterol Turbuhaler at cumulative dose of 90 ug in patients acute bronchial obstruction Eur Respir J 18 2001 928-934
24. R. Kaae L. Agertoft S. Pedersen et al. Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6-11 years of age than cumulative high doses of inhaled terbutaline Br J Clin Pharmacol 58 4 2004 411-418